D}~}6/z!}@K DJlAJcF

Y] #]_ s):sC\cC& u *J*iPJ6i sm:U2U^2:m 7Y xl?hw ??A= 0l]|| n_+jH%+ji G(p -k-kwjk-[j )!blMBFl\T K9s )AA)Z+. /t;=tyt :g e1YP ,LKT0iU n* $WVH^V QOVNy:MFyO: rU,?7$U-r ^lllz WG 0IPK }pgH ? Iw,4I4TcvB v#V *#HHT/Q ,f/T1/ 4! ;Ym;ti w+~`*!~w.

o5%N5eYi
Rqflzfl 8Nkm WQ `bNbJ5&D
D6^qC
a^O~5uZ~U^v
J::75::
a^O~5uZ~U^v
B;
a^O~5uZ~U^v
eYe `:
a^O~5uZ~U^v
Z\Z {g?
a^O~5uZ~U^v
`T daU
a^O~5uZ~U^v
k7k #=m
a^O~5uZ~U^v
8t8 yTQpT l0M4 gDG`J
a^O~5uZ~U^v
yH?@w]_Y`1 UcpTUp| K@)(mm xr_JQ)r)1J58
a^O~5uZ~U^v
kq %yyᵃ
a^O~5uZ~U^v
I{I Ug
a^O~5uZ~U^v
tkt 1||
a^O~5uZ~U^v
k7k #=m
a^O~5uZ~U^v
#d# // #HT} \EwwJw/C
a^O~5uZ~U^v
AIYwISe
a^O~5uZ~U^v
*%Ri)) V~03Z#~#z3!h
a^O~5uZ~U^v
*%Ri)) V~03Z#~#z3!h
a^O~5uZ~U^v
BjB w&x ,+G |d| ;BB
a^O~5uZ~U^v
#B9u)) K0plgN0NTl0`
a^O~5uZ~U^v
K5K z]P
a^O~5uZ~U^v
K7K (UZ4U
a^O~5uZ~U^v
epR$0p} :t:qcr\LqT Kvv3t7v183~
a^O~5uZ~U^v
R~o~j eP1t$mYm9
a^O~5uZ~U^v
YPP(yNZNs@ k39+; Q(~Dm::moQj(
a^O~5uZ~U^v
n~B7A6!7X ,U, {;nkqq e-&-(-n(-;& aSWm:mWm`Ao
a^O~5uZ~U^v
@Z 019-\ Rwz[z
a^O~5uZ~U^v
Tc Ba Uw&`&
a^O~5uZ~U^v
EokW gW_9_
a^O~5uZ~U^v
{`8a_|k Vn=A=
a^O~5uZ~U^v
!r -2*2JuJ
a^O~5uZ~U^v
(z RB$$
a^O~5uZ~U^v
I! DHxx
a^O~5uZ~U^v
s8 (&00
a^O~5uZ~U^v
Gv y1fy(F1
a^O~5uZ~U^v
e4 `02
a^O~5uZ~U^v
0p ]SS
a^O~5uZ~U^v
$t r)1
a^O~5uZ~U^v
\l7) o||
a^O~5uZ~U^v
yu ++h3h kcDV)D9:LjlDc L7]bsXH?@7*O
a^O~5uZ~U^v
%& T;h;V *c@* o[aua
a^O~5uZ~U^v
d&UxU |sfk 8gcS%JW-=%gc
a^O~5uZ~U^v
nu ),^ bK$35 w{k=FN
a^O~5uZ~U^v
nu ),^ bK$35 w{k=FN
a^O~5uZ~U^v
nu ),^ bK$35 w{k=FN
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
IIIz[{[
a^O~5uZ~U^v
(z RB$$
a^O~5uZ~U^v
Ws i93*3ᵇ
a^O~5uZ~U^v
je7+#4S 3-totᵇ
a^O~5uZ~U^v
{Lm b*c@cᵇ
a^O~5uZ~U^v
)T E+d22ᵇ
a^O~5uZ~U^v
Za q::g* +-^
a^O~5uZ~U^v
7, a}CMj !,i
a^O~5uZ~U^v
JUs[I@T[_ W\
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
H~ UjW K/Qlit $Q/J
a^O~5uZ~U^v
@7 S$\$
a^O~5uZ~U^v
oI}v9}9DID
a^O~5uZ~U^v
,j8ja,a
a^O~5uZ~U^v
~dS RPlP M?c?Q?=Q?)c 347CXC7C0O-
a^O~5uZ~U^v
ymV=m
a^O~5uZ~U^v
7H+K+ GIh~%6
a^O~5uZ~U^v
gygF HyR yU
a^O~5uZ~U^v
7H+K+ GIh~%6

Fn ?* {TLTOd R}R\

TAmgen collaboration; BeiGene has China commercial rights. cEnsem collaboration; BeiGene has global rights. ODualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. wLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. #Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. eAmgen collaboration; BeiGene has development and commercialization rights in China. tIn combination with Zanubrutinib. sMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login